Navigation Links
Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
Date:4/3/2013

CARLSBAD, Calif., April 3, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated a Phase 1 clinical study for ISIS-APOARx, an antisense drug targeting apolipoprotein(a) for the treatment of atherosclerosis.  Apolipoprotein(a) contributes to the formation of plaque in arteries through its attachment to an LDL-C particle in a complex termed lipoprotein(a), or Lp(a).  High levels of Lp(a) are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke.  ISIS-APOARx is designed to reduce Lp(a) by inhibiting the production of apolipoprotein(a).  Isis plans to develop ISIS-APOARx to treat patients with high Lp(a) levels who are at high risk of experiencing cardiovascular events.

"Lp(a) is an independent risk factor for coronary heart disease.  Although Lp(a) can be measured during a routine lipid blood panel, the lack of drugs that effectively lower Lp(a) have made treating patients with high Lp(a) levels difficult.  Because elevated Lp(a) is an inherited genetic condition, patients are unable to adequately control their Lp(a) levels through diet or lifestyle changes.  By inhibiting the production of apolipoprotein(a), ISIS-APOARx is designed to reduce the levels of Lp(a), thereby offering a unique and specific approach to treating patients who have high cardiovascular risk due to high Lp(a) levels,"  said Walter Singleton , M.D., vice president of development and chief medical officer at Isis.  "ISIS-APOARx is part of Isis' strategy to create a cardiovascular disease franchise comprised of drugs that target all the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis."

The Phase
'/>"/>

SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
2. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
3. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
4. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
5. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
6. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
7. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
8. Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
9. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
10. uniQure Initiates Phase I in Acute Intermittent Porphyria
11. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... , August 29, 2014 ... Oil Market by Extraction type (SFE, Cold Pressed, ... Personal Care, Pharmaceutical, Food Supplements, Fragrance, & Others) - ... MarketsandMarkets, defines and segments the Amaranth Seed Oil ... market size in terms of value. The Amaranth ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:China Orthopedic Instrument Industry Report, 2014-2017 2Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4District Court Decision Received In Remodulin Patent Case 2
... , MONMOUTH JUNCTION, N.J., Oct. 19 Transave Inc., ... lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an ... The latest results along with previously reported data demonstrate ... program in two indications - for the treatment of ...
... WORTH, Texas, Oct. 19 Galderma Laboratories proudly announces ... Cetaphil® UVA/UVB Defense SPF 50 have recently been granted ... Good Housekeeping Research Institute. , The Good Housekeeping Seal ... "tested and approved" emblems in the U.S. , "It ...
Cached Medicine Technology:Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 2Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 3Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 4Transave Completes Successful Phase II Clinical Program for ARIKACE in the Treatment of Pseudomonas Lung Infections 5Three Cetaphil(R) Products Earn Good Housekeeping Seal 2
(Date:8/30/2014)... The SI Joint Evaluation and Treatment covers ... energy techniques. Michael P. Reiman PT, DPT, OCS, SCS, ... for the SI Joint. This PT online ... presentation with North American Seminars. , PT ... differential diagnosis approach to a thorough examination of the ...
(Date:8/30/2014)... What challenges exist in recruiting top talent ... concerns, and considerations? Sports Conflict Institute ’s ... with Woody Wommack, Southeast Football Recruiting Analyst of Rivals.com/Yahoo! ... recruiting. Notably, Wommack spoke on what the recruiting ... thinks are coming as a result of the O’Bannon ...
(Date:8/30/2014)... 30 August 2014: A new sudden death predictor ... for implantable cardioverter defibrillators (ICDs) in ESC Guidelines ... by Task Force Chairperson Professor Perry Elliott (UK). ... Management of Hypertrophic Cardiomyopathy" are published today on-line ... and on the ESC Website. Previous ESC Guidelines ...
(Date:8/29/2014)... Cancer is a life-changing illness that ... Eddie M. Leung knows the suffering that patients go through; ... cancer, a very rare and aggressive form of cancer. In ... by Xlibris), he shares a glimpse into his struggles as ... testimony that this disease can be overcome. , ...
(Date:8/29/2014)... Denver, Colorado (PRWEB) August 29, 2014 Daily Gossip ... the program was created by a former cold sores patient who ... this method is Ellie Gadsby, who decided to share her tips ... the world. , The author of the Get Rid of ... sores for 22 years, while in the least 4 years outbreaks ...
Breaking Medicine News(10 mins):Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 2Health News:Woody Wommack of Rivals.com Discusses the World of NCAA Football Recruiting on SCI TV 3Health News:Sudden death predictor identifies ICD candidates in new ESC Guidelines 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3Health News:Get Rid of Cold Sores Fast Review Reveals Simple Way to Eliminate Cold Sores in 12 Hours 2
... Hill-Rom Holdings, Inc. (NYSE: HRC ) today ... share. This dividend was declared by Hill-Rom,s Board of Directors ... 2009 to shareholders of record as of March 17, 2009. ... is a leading worldwide manufacturer and provider of medical technologies ...
... potential partners is easier to read than women,s, speed-dating study ... unattached this Valentine,s Day and you,re hoping to change that, ... easier to judge how interested a man is than it ... , Men who are attracted to women, it seems, are ...
... SYDNEY, Feb. 13 /PRNewswire-,FirstCall/ -- Thoratec Corporation ... leader in device-,based mechanical circulatory support therapies ... HeartWare International (ASX: HIN), which develops and,manufactures ... they,have entered into a definitive merger agreement ...
... through. , ... (Vocus) February 13, 2009 -- For centuries Mardi Gras - also known ... last bits of fat and meat in millions of homes in preparation for ... favorite foods. Meat is often chosen for this observance, as indicated by ...
... The Ensign Group, Inc. (Nasdaq: ... group of skilled nursing, rehabilitative care services and ... to issue its fourth quarter and fiscal year ... Wednesday, February 18, 2009.(Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) ...
... also affect chances of having debilitating headaches , , THURSDAY, Feb. ... of migraine headaches in young and middle-aged adults, suggests a ... and the way body fat was distributed affected migraine risk. ... more likely to have migraines than those with smaller waistlines. ...
Cached Medicine News:Health News:Men, the Obvious Sex 2Health News:Men, the Obvious Sex 3Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 2Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 3Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 4Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 5Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 6Health News:Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million; 7Health News:Mardi Gras Gives Everyone a Big Fat Break Because Carnival Means "So Long" to Meat 2Health News:Mardi Gras Gives Everyone a Big Fat Break Because Carnival Means "So Long" to Meat 3Health News:The Ensign Group Schedules 2008 Year End Earnings Call for Thursday, February 19, 2009 2Health News:Belly Fat May Make Migraines More Likely 2
... a combination of innovative design, consistently reliable ... I-125 implant an ideal choice for your ... every BrachySource I-125 implant order is backed ... required by clinicians who must meet the ...
... BrachySource iodine-125 implant is a combination of ... visibility that makes BrachySource I-125 implant an ... can be confident that every BrachySource I-125 ... management services which is required by clinicians ...
The silicone Tractfinder provides excellent fluoroscopic visualization. Manipulation of the movable core guidewire flexes the tapered proximal tip for maximum control in negotiating a tortuous ureter...
... Used for temporary internal drainage from the ... of a stricture. The segment with no ... lumen while preventing ingrowth of the ureteral ... peel-open packages. Intended for one-time use. CAUTION: ...
Medicine Products: